Individual profiling of circulating tumor cell composition and therapeutic outcome in patients with hepatocellular carcinoma

Translational Oncology

Volumn 6, Issue 4, 2013, Pages 420-428

  Nel, Ivonne ^a   Baba, Hideo A ^a   Ertle, Judith ^a   Weber, Frank ^a   Sitek, Barbara ^b   Eisenacher, Martin ^b   Meyer, Helmut E ^b   Schlaak, Joerg F ^a   Hoffmann, Andreas Claudius ^a  

^a UNIVERSITY HOSPITAL ESSEN   (Germany)

^b RUHR UNIVERSITY BOCHUM   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CD45 ANTIGEN; NERVE CELL ADHESION MOLECULE; VIMENTIN;

ADULT; AGED; ARTICLE; CELL HETEROGENEITY; CIRCULATING TUMOR CELL; CLINICAL ARTICLE; CONTROLLED STUDY; DENSITY GRADIENT CENTRIFUGATION; DISEASE ASSOCIATION; EPITHELIAL MESENCHYMAL TRANSITION; FOLLOW UP; HUMAN; HUMAN CELL; IMMUNOCYTOCHEMISTRY; IMMUNOFLUORESCENCE; IMMUNOMAGNETIC SEPARATION; LIVER CELL CARCINOMA; TREATMENT RESPONSE; TUMOR VOLUME;

EID: 84881075689     PISSN: None     EISSN: 19365233     Source Type: Journal    
DOI: 10.1593/tlo.13271     Document Type: Article

References (30)

1. Llovet JM, Burroughs A, and Bruix J (2003). Hepatocellular carcinoma. Lancet 362, 1907-1917.
2. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D (2011). Global cancer statistics. CA Cancer J Clin 61, 69-90.
3. Belghiti J, Panis Y, Farges O, Benhamou JP, and Fekete F (1991). Intrahepatic recurrence after resection of hepatocellular carcinoma complicating cirrhosis. Ann Surg 214, 114-117.
4. Arriagada R, Bergman B, Dunant A, Le Chevalier T, Pignon JP, and Vansteenkiste J (2004). Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer. N Engl J Med 350, 351-360.
5. Winton T, Livingston R, Johnson D, Rigas J, Johnston M, Butts C, Cormier Y, Goss G, Inculet R, Vallieres E, et al. (2005). Vinorelbine plus cisplatin vs. observation in resected non-small-cell lung cancer. N Engl J Med 352, 2589-2597.
6. Olaussen KA, Dunant A, Fouret P, Brambilla E, André F, Haddad V, Taranchon E, Filipits M, Pirker R, Popper HH, et al. (2006). DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy. N Engl J Med 355, 983-991.
7. Sangro B, Bilbao JI, Boan J, Martinez-Cuesta A, Benito A, Rodriguez J, Panizo A, Gil B, Inarrairaegui M, Herrero I, et al. (2006). Radioembolization using 90Y-resin microspheres for patients with advanced hepatocellular carcinoma. Int J Radiat Oncol Biol Phys 66, 792-800.
8. Lau WY, Lai EC, and Leung TW (2011). Current role of selective internal irradiation with yttrium-90 microspheres in the management of hepatocellular carcinoma: a systematic review. Int J Radiat Oncol Biol Phys 81, 460-467.
9. Sun YF, Yang XR, Zhou J, Qiu SJ, Fan J, and Xu Y (2011). Circulating tumor cells: advances in detection methods, biological issues, and clinical relevance. J Cancer Res Clin Oncol 137, 1151-1173.
10. Lianidou ES and Markou A (2011). Circulating tumor cells in breast cancer: detection systems, molecular characterization, and future challenges. Clin Chem 57, 1242-1255.
11. Hou JM, Krebs M, Ward T, Sloane R, Priest L, Hughes A, Clack G, Ranson M, Blackhall F, and Dive C (2011). Circulating tumor cells as a window on metastasis biology in lung cancer. Am J Pathol 178, 989-996.
12. Zhang N, Li X, Wu CW, Dong Y, Cai M, Mok MT, Wang H, Chen J, Ng SS, Chen M, et al. (2012). microRNA-7 is a novel inhibitor of YY1 contributing to colorectal tumorigenesis. Oncogene. DOI: 10.1038/onc.2012.526, E-pub ahead of print.
13. Waguri N, Suda T, Nomoto M, Kawai H, Mita Y, Kuroiwa T, Igarashi M, Kobayashi M, Fukuhara Y, and Aoyagi Y (2003). Sensitive and specific detection of circulating cancer cells in patients with hepatocellular carcinoma; detection of human telomerase reverse transcriptase messenger RNA after immunomagnetic separation. Clin Cancer Res 9, 3004-3011.
14. Xu W, Cao L, Chen L, Li J, Zhang XF, Qian HH, Kang XY, Zhang Y, Liao J, Shi LH, et al. (2011). Isolation of circulating tumor cells in patients with hepato-cellular carcinoma using a novel cell separation strategy. Clin Cancer Res 17, 3783-3793.
15. Vona G, Estepa L, Beroud C, Damotte D, Capron F, Nalpas B, Mineur A, Franco D, Lacour B, Pol S, et al. (2004). Impact of cytomorphological detection of circulating tumor cells in patients with liver cancer. Hepatology 39, 792-797.
16. Guo J, Yao F, Lou Y, Xu C, Xiao B, Zhou W, Chen J, Hu Y, and Liu Z (2007). Detecting carcinoma cells in peripheral blood of patients with hepatocellular carcinoma by immunomagnetic beads and RT-PCR. J Clin Gastroenterol 41, 783-788.
17. Schulze K, Beneken C, Staufer K, Nashan B, Lohse AW, Pantel K, Riethdorf S, and Wege H (2011). Detection of Epcam-positive circulating tumor cells in patients with hepatocellular carcinoma-a pilot study. Hepatology 54, 1357a.
18. Krebs MG, Hou JM, Sloane R, Lancashire L, Priest L, Nonaka D, Ward TH, Backen A, Clack G, Hughes A, et al. (2012). Analysis of circulating tumor cells in patients with non-small cell lung cancer using epithelial marker-dependent and -independent approaches. J Thorac Oncol 7, 306-315.
19. Ignatiadis M, Georgoulias V, and Mavroudis D (2008). Circulating tumor cells in breast cancer. Curr Opin Obst Gynecol 20, 55-60.
20. Ignatiadis M, Georgoulias V, and Mavroudis D (2008). Micrometastatic disease in breast cancer: clinical implications. Eur J Cancer 44, 2726-2736.
21. Hoffmann A-C (2009). A three-gene signature for outcome in soft tissue sarcoma. Clin Cancer Res 15, 6472.
22. Hoffmann A-C, Mori R, Vallbohmer D, Brabender J, Klein E, Drebber U, Baldus SE, Cooc J, Azuma M, Metzger R, et al. (2008). High expression of HIF1a is a predictor of clinical outcome in patients with pancreatic ductal adenocarcinomas and correlated to PDGFA, VEGF, and bFGF. Neoplasia 10, 674-679.
23. Hoffmann A-C, Wild P, Leicht C, Bertz S, Danenberg KD, Danenberg PV, Stoehr R, Stoeckle M, Lehmann J, Schuler M, et al. (2010). MDR1 and ERCC1 expression predict outcome of patients with locally advanced bladder cancer receiving adjuvant chemotherapy. Neoplasia 12, 628-636.
24. Yu M, Stott S, Toner M, Maheswaran S, and Haber DA (2011). Circulating tumor cells: approaches to isolation and characterization. J Cell Biol 192, 373-382.
25. Yu M, Bardia A, Wittner BS, Stott SL, Smas ME, Ting DT, Isakoff SJ, Ciciliano JC, Wells MN, Shah AM, et al. (2013). Circulating breast tumor cells exhibit dynamic changes in epithelial and mesenchymal composition. Science 339, 580-584.
26. Gradilone A, Raimondi C, Nicolazzo C, Petracca A, Gandini O, Vincenzi B, Naso G, Agliano AM, Cortesi E, and Gazzaniga P (2011). Circulating tumour cells lacking cytokeratin in breast cancer: the importance of being mesenchymal. J Cell Mol Med 15, 1066-1070.
27. Raimondi C, Gradilone A, Naso G, Vincenzi B, Petracca A, Nicolazzo C, Palazzo A, Saltarelli R, Spremberg F, Cortesi E, et al. (2011). Epithelial-mesenchymal transition and stemness features in circulating tumor cells from breast cancer patients. Breast Cancer Res Treat 130, 449-455.
28. Joly E and Hudrisier D (2003). What is trogocytosis and what is its purpose? Nat Immunol 4, 815.
29. Allard WJ, Matera J, Miller MC, Repollet M, Connelly MC, Rao C, Tibbe AG, Uhr JW, and Terstappen LW (2004). Tumor cells circulate in the peripheral blood of all major carcinomas but not in healthy subjects or patients with nonmalignant diseases. Clin Cancer Res 10, 6897-6904.
30. Marrinucci D, Bethel K, Bruce RH, Curry DN, Hsieh B, Humphrey M, Krivacic RT, Kroener J, Kroener L, Ladanyi A, et al. (2007). Case study of the morphologic variation of circulating tumor cells. Hum Pathol 38, 514-519.